1 nts were randomly assigned to receive either volasertib 300 mg by intravenous infusion every 3 weeks

2 ice daily subcutaneously days 1-10 or LDAC + volasertib 350 mg IV days 1 + 15 every 4 weeks.

3 d low-dose cytarabine (LDAC) with or without volasertib, a highly potent and selective inhibitor of p

4        Pharmacologic inhibition of PLK1 with volasertib, a small-molecule ATP-competitive PLK1 inhibi

5                 Six patients (11%) receiving volasertib achieved PFS fore more than 1 year, whereas n

6 09 patients receiving treatment, 54 received volasertib and 55 received chemotherapy; demographics we

7 Median PFS was 13.1 weeks and 20.6 weeks for volasertib and chemotherapy (hazard ratio, 1.01; 95% CI,

8 seven (13.0%) and 15 (27.3%) patients in the volasertib and chemotherapy arms, respectively.

9        The 24-week disease control rates for volasertib and chemotherapy were 30.6% (95% CI, 18.0% to

10                      Responses in the LDAC + volasertib arm were observed across all genetic groups,

11 rvival was significantly prolonged by LDAC + volasertib compared with LDAC (5.6 vs 2.3 months; hazard

12                        Patients treated with volasertib experienced more grade 3 and 4 drug-related h

13                                              Volasertib in combination with the ER antagonist, fulves

14                                              Volasertib is a potent and selective cell-cycle kinase i

15                                       LDAC + volasertib led to an increased frequency of adverse even

16                This phase II trial evaluated volasertib or single-agent chemotherapy in patients with

17 ition of PLK2 by the PLK inhibitor, BI 6727 (volasertib), or PLK2 knockdown was proapoptotic in CCA c

18                                 Single-agent volasertib showed antitumor activity in patients with ov

19 L-xL) mRNA levels were markedly reduced upon volasertib treatment in MCF7/LTED cells, while they were

20  blood count recovery) was higher for LDAC + volasertib vs LDAC (31.0% vs 13.3%; odds ratio, 2.91; P

21                    AEs in patients receiving volasertib were mainly hematologic and manageable.